A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether lenalidomide is safe and effective in the
treatment of patients with newly diagnosed Multiple Myeloma who are 65 years of age or older.